AlphAIAlphAI — Financial news for AI agents
businesskorea.co.krNOV 42 min read

Lonza Acquires Merck U.S. CDMO Facilities, Competing with Samsung Biologics

Lonza, a Swiss CDMO company, will acquire five U.S. facilities from Merck for 100-600 million Swiss francs, expanding its U.S. presence to nine locations and adding 1,100 employees. The acquired facilities are expected to generate 250 million Swiss francs in annual revenue by 2028. Samsung Biologics is also expanding, acquiring Polypeptide Group for 1.46 billion Swiss francs.

Original reporting
businesskorea.co.kr
Published Nov 4, 2026, 12:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 1:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMergers & acquisitions
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$MRK
Relevance
8/10
AlphAI data visualization · based on businesskorea.co.kr
Decision brief

The 30-second read

High
01

Why it matters

The acquisition positions Lonza as a larger player in U.S. biologics manufacturing, potentially driving its stock higher, while Merck's divestiture may weigh on its share price.

02

Market read

A material M&A deal in the biotech manufacturing space with immediate pricing implications for both Lonza and Merck.

03

What to watch

Regulatory approvals and integration risks could delay expected synergies for Lonza.

Relevance 8/10Novelty 8/10Timing: today

Background

Lonza, a Swiss CDMO, is expanding its U.S. footprint by acquiring Merck's five facilities, while Samsung Biologics pursues a separate CDMO deal.

Market effects

Sector

Consolidation in the CDMO sector may boost peers with similar capabilities.

Regional

Strengthens the U.S. biotech manufacturing ecosystem, potentially benefiting related biotech stocks.

Global

Highlights ongoing competition between Lonza and Samsung Biologics for global CDMO market share.

Counterpoint

What could challenge this read

Merck could redeploy capital into higher‑margin R&D, offsetting short‑term revenue loss.

Key entities

  • Company
    Lonza Group AG

    Swiss CDMO expanding U.S. operations.

  • Company
    Merck KGaA

    German pharmaceutical company selling U.S. CDMO assets.

Read at source← All news

StoryLonza to acquire Merck KGaA’s five U.S. CDMO sites

Also covered by

6 outlets

Related articles

NOV 4
Med

Germany: Lonza agrees to acquire Merck’s US CDMO business, expanding its footprint to nine sites

Lonza, a Swiss CDMO, will acquire Merck KGaA's US CDMO business for low- to mid-triple-digit millions of Swiss francs. The deal expands Lonza's US sites from 4 to 9 and adds 1,100 employees. Merck retains its BioReliance Contract Testing Services. Lonza expects CHF 250m in sales from the acquired sites by 2028, with minimal group impact. The transaction is cash-funded and maintains Lonza's BBB+ rating.

investorsinhealthcare.com2 min
NOV 4
$MRKMedAI 8/10

Lonza to Acquire Five Merck CDMO Sites, Doubles US Manufacturing Footprint

Lonza is acquiring five CDMO facilities from Merck KGaA for low to mid-triple-digit millions of Swiss francs, expanding its US presence. The deal adds nine facilities, 1,100 employees, and capabilities in bioconjugates, viral vectors, and advanced drug delivery. Lonza expects CHF 250M in sales by 2028, with integration expected to drive future growth. The transaction is set to close by mid-2027.

chemanalyst.com6 min
NOV 4
$MRKMedAI 9/10

Merck to Sell CDMO Business to Lonza

Merck agreed to sell its contract development and manufacturing (CDMO) business to Lonza for a mid-triple-digit million-euro amount. The deal, expected to close in mid-2027, aligns with Merck's strategy to focus on innovation-driven businesses. Lonza will expand its US manufacturing capabilities through the acquisition, while Merck will retain its BioReliance® Contract Testing Services.

chemindigest.com3 min